Therefore, antagonism of CXCR2 has been demonstrated to work in combination with traditional chemotherapeutic agents in decreasing cellular senescence and malignancy, primarily through a decrease in MDSC tumor infiltration [189]. The gene discussed is CXCR2; the disease is neoplasm.